Irritable Bowel Syndrome Clinical Trial
Official title:
Resilience in Irritable Bowel Syndrome and Gut-focused Hypnotherapy: Longitudinal Study With Hypnotherapy Patients and Cross Sectional Control Group
Background:
Resilience refers to a class of variables highly relevant for wellbeing and coping with
stress, trauma, and chronic adversity. Despite its significance for health, resilience is
hardly examined empirically and suffers from poor conceptual integration. Irritable bowel
syndrome (IBS) is a functional disorder with altered psychological stress reactivity and
brain-gut-microbiota axis, which causes high chronic strain. Gut-focused hypnotherapy (GHT)
is a standardized treatment for IBS targeting at resilience. An increase of resilience by
GHT has been hypothesized but requires further investigation.
Aims of the study were construct validation and development of an integrational measure of
different resilience domains by dimensional reduction, and investigation of change in
resilience in IBS patients by GHT.
N=74 Gastroenterology outpatients with Irritable Bowel Syndrome (Rome III criteria) were
examined in 7 resilience domains, quality of life, psychological distress and symptom
severity. n=53 of these participate in 7 to 10 Gut-directed Hypnotherapy group sessions
(Manchester protocol). Post-treatment examinations were performed 10 months after last GHT
session.
Aims of this study were, to measure detailed factors of resilience by adequate psychological
instruments in a sample of Irritable Bowel Syndrome (IBS) patients and to investigate
whether they are facets of the same underlying construct. To calculate a composite measure
of resilience based on obtained insights concerning the structure of resilience. To test the
hypothesis of a positive relation between resilience and response to therapy. And finally,
to investigate differences between patients untreated or treated with Gut-directed
Hypnotherapy in groups cross-sectionally and longitudinally, to test the hypothesis of a
presumed increase in resilience (using the composite score) with changes in IBS symptoms,
quality of life and psychological distress in parallel.
Study location and recruitment:
N=74 Irritable bowel syndrome patients (diagnosed according to Rome III criteria) aged
between 18 and 70 and refractory to other therapies were recruited at the Specialized
outpatient-clinic for Psychosomatics at the Division of Gastroenterology and Hepatology,
Department for Internal Medicine III, University Hospital of Vienna. Antidepressants or
anxiolytics and/or ongoing psychotherapy were allowed since severe comorbid psychological
problems are a common problem in IBS patients. The study protocol was approved by the ethics
committee of the Medical University of Vienna (ID: 1488/2012). Informed consent in writing
was given by each participant.
Study Design and Treatment:
Cross-sectional comparisons were performed with data of n = 37 GHT treated and n = 37
untreated patients (control group) post GHT. This data were pooled for dimensional reduction
of resilience domains. Resilience and IBS severity data from the treatment group were
assessed post GHT; psychological distress and quality of life were assessed pre and post
GHT. A fraction of n = 16 of the untreated patients (former control group) subsequently also
received GHT treatment. Pre and post GHT data of these patients were collected and then used
for longitudinal comparisons, along with the pre and post GHT data on psychological distress
and quality of life of the primary treatment group. In total, N= 74 patients were examined,
in total 53 (= 37 + 16) of which underwent GHT. Post treatment examinations were performed
10 months after last GHT session. The GHT protocol used was the Manchester protocol of GHT
and consisted of 10 weekly sessions (45 min), with six patients per group over a treatment
period of 12 weeks. GHT was performed at the University Hospital by two experienced
physicians trained in Manchester (UK).
;
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A |